Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2322470rdf:typepubmed:Citationlld:pubmed
pubmed-article:2322470lifeskim:mentionsumls-concept:C1556094lld:lifeskim
pubmed-article:2322470lifeskim:mentionsumls-concept:C0010346lld:lifeskim
pubmed-article:2322470lifeskim:mentionsumls-concept:C0062872lld:lifeskim
pubmed-article:2322470lifeskim:mentionsumls-concept:C0332281lld:lifeskim
pubmed-article:2322470pubmed:issue2lld:pubmed
pubmed-article:2322470pubmed:dateCreated1990-5-14lld:pubmed
pubmed-article:2322470pubmed:abstractTextThe association of Crohn's disease (CD) with the HLA system was investigated in Japanese patients by serological and genomic methods. HLA antigens were typed in 30 unrelated Japanese patients with CD and 54 healthy controls. The frequencies of HLA-DR4, DRw53 and DQw3 antigens were increased in CD (76.7, 86.7 and 80.0%) compared with controls [37.0%, p corrected (pc) = 0.007; 52.9%, pc = 0.001; 52.0%, pc = 0.009]. DQw7 and DQw8 antigens, the new split antigens of DQw3 produced by the TA10 antibody and linked to the DR4 and DRw53 antigens, were not significantly different in the DQw3-positive CD and controls. Class I antigens were not significantly different in the CD and controls. HLA-DR-B and DQ-B probes were used to study PstI-generated restriction fragment length polymorphism (RFLP) in CD and controls. The DRw53-specific PstI DR-B 2.6-kb fragment was increased in CD (88.0%) compared with controls (37.5%, pc = 5.6 X 10(-4)). The PstI DR-B 3.2-kb fragment was also increased in CD (80.0%) compared with controls (35.0%, pc = 5.6 X 10(-3)). It is reasonable to infer that the DRw53 is the most important susceptibility antigen in Japanese CD. The subtypes of the DR4 were determined by the hybridization of the DQ-B probe. The DQ-B PstI fragment patterns were not different in CD and controls.lld:pubmed
pubmed-article:2322470pubmed:languageenglld:pubmed
pubmed-article:2322470pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2322470pubmed:citationSubsetIMlld:pubmed
pubmed-article:2322470pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2322470pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2322470pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2322470pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2322470pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2322470pubmed:statusMEDLINElld:pubmed
pubmed-article:2322470pubmed:issn0254-9670lld:pubmed
pubmed-article:2322470pubmed:authorpubmed-author:KobayashiKKlld:pubmed
pubmed-article:2322470pubmed:authorpubmed-author:AndoAAlld:pubmed
pubmed-article:2322470pubmed:authorpubmed-author:SekiguchiSSlld:pubmed
pubmed-article:2322470pubmed:authorpubmed-author:InokoHHlld:pubmed
pubmed-article:2322470pubmed:authorpubmed-author:KonoedaYYlld:pubmed
pubmed-article:2322470pubmed:authorpubmed-author:YagitaAAlld:pubmed
pubmed-article:2322470pubmed:authorpubmed-author:AtohMMlld:pubmed
pubmed-article:2322470pubmed:issnTypePrintlld:pubmed
pubmed-article:2322470pubmed:volume7lld:pubmed
pubmed-article:2322470pubmed:ownerNLMlld:pubmed
pubmed-article:2322470pubmed:authorsCompleteYlld:pubmed
pubmed-article:2322470pubmed:pagination101-8lld:pubmed
pubmed-article:2322470pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:2322470pubmed:meshHeadingpubmed-meshheading:2322470-...lld:pubmed
pubmed-article:2322470pubmed:meshHeadingpubmed-meshheading:2322470-...lld:pubmed
pubmed-article:2322470pubmed:meshHeadingpubmed-meshheading:2322470-...lld:pubmed
pubmed-article:2322470pubmed:meshHeadingpubmed-meshheading:2322470-...lld:pubmed
pubmed-article:2322470pubmed:meshHeadingpubmed-meshheading:2322470-...lld:pubmed
pubmed-article:2322470pubmed:meshHeadingpubmed-meshheading:2322470-...lld:pubmed
pubmed-article:2322470pubmed:meshHeadingpubmed-meshheading:2322470-...lld:pubmed
pubmed-article:2322470pubmed:meshHeadingpubmed-meshheading:2322470-...lld:pubmed
pubmed-article:2322470pubmed:year1990lld:pubmed
pubmed-article:2322470pubmed:articleTitleCrohn's disease in the Japanese is associated with the HLA-DRw53.lld:pubmed
pubmed-article:2322470pubmed:affiliationDepartment of Laboratory Medicine, National Defense Medical College, Tokorozawa, Japan.lld:pubmed
pubmed-article:2322470pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2322470pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2322470lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2322470lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2322470lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2322470lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2322470lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2322470lld:pubmed